PIP-101 is claimed to reduce or hinder the growth of some types of leukaemia. Credit: Ed Uthman / Flickr
(Creative Commons)
.
Shorla Oncology has signed a
licensing agreement and strategic collaboration
with an undisclosed drug development and production firm in the UK for a chemotherapy drug, PIP-101.
Shorla will obtain a licence from the UK company to register and market the drug in the US.
Recommended Reports
Reports
LOA and PTSR Model - Desidustat in Chemotherapy Induced Anemia
GlobalData
Reports
LOA and PTSR Model - Sulanemadlin in Chemotherapy Induced Myelosuppression
GlobalData
View all
Companies Intelligence
Shorla Pharma Ltd
View all
PIP-101 is an oral solution that reduces or hinders the growth of some types of leukaemia, including chronic myeloid leukaemia and acute lymphoblastic leukaemia.
The developer will produce PIP-101 and once Shorla receives a new drug application clearance, it will oversee the launch, marketing and sales of the drug in the US.
Shorla Oncology CEO and co-founder Sharon Cunningham stated: “We are excited to partner with and leverage the developer’s oral oncology liquid manufacturing expertise.
“This commercial partnership is a strong endorsement of our commitment to bring to market differentiated oncology treatments to address key areas of unmet needs for patients.”
In March 2023, the company received approval from
the US Food and Drug Administration for its Nelarabine injection
to treat T-cell leukaemia.
The company is partnering with Eversana to launch this injection commercially.
By the end of 2024, Shorla anticipates making its three products available in the market and having at least three further products at a developmental stage.